GCM
ATYR icon

Gruss Capital Management’s aTyr Pharma ATYR Stock Holding History

Gruss Capital Management’s Portfolio ATYR Stock Details ATYR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-1,071
Closed -$2.36M – 45
2016
Q1 		$2.36M Buy
+1,071
New +$3.26M 0.07% 40

Other funds holding ATYR

RCM
Riverhead Capital Management Wilmington, Delaware $2.71B AUM 2.34% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Polaris Venture Management Co V
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Rock Springs Capital Management
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BlackRock Fund Advisors
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
TAM
Tiverton Asset Management Wilimington, Delaware $2.88B AUM 5.6% 1-Year Est. Return
BlackRock Institutional Trust
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Gruss Capital Management's ATYR Position: Q2 2016 in Review

Gruss Capital Management sold out of aTyr Pharma (ATYR) in Q2 2016, closing a stake of 1,071 shares — an estimated $2.36M sold.

Gruss Capital Management first reported a position in ATYR in Q1 2016 and held it in 1 quarter. The position peaked at $2.36M in Q1 2016. 49 funds tracked by Wall St. Rank hold ATYR as of Q2 2016.

  • Gruss Capital Management reported no remaining aTyr Pharma position as of Q2 2016 after selling out during the quarter.
  • Gruss Capital Management sold 1,071 aTyr Pharma shares in Q2 2016, an estimated $2.36M.
  • Gruss Capital Management first reported a position in aTyr Pharma in Q1 2016 and held it in 1 quarter.
  • Gruss Capital Management's aTyr Pharma position peaked at $2.36M in Q1 2016.
  • 49 funds tracked by Wall St. Rank held aTyr Pharma as of Q2 2016.

Based on Gruss Capital Management's 13F filing for Q2 2016, filed 12 Aug 2016.